Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer. 2011; 104 (5):741–745. doi: 10.1038/sj.bjc.6606061. [ Cross Ref ]Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A. et al. Sunitinib and other targeted therapies for renal cell carcinoma. Br J...
remain the first-line drugs for the treatment of mRCC. Acquired drug resistance and metastasis are the main causes of treatment failure. However, in the case of metastasis Renal Cell Cancer (mRCC), which showed a good response to sunitinib, we found that long-term treatment with sunitinib coul...
renal cell carcinoma (RCC) is a common malignancy of the urinary system and represents a serious threat to human health. Although the overall survival of RCC has improved substantially with the development of cancer diagnosis and management, there are various reasons for treatment failure....
N., TokudaH., UchinoF., MorokumaTokuda N, et al. Pre-surgical sunitinib treatment for renal cell carcinoma: A case series. Urology 84 (Suppl. 4): S173 abstr. 009, Oct 2014. Available from: URL: http://.org/10.1016/S0090-4295%2814%2901020-6 [abstract] - ...
In addition, sunitinib can increase the expression of LncRNA SARCC, thereby reducing RCC cell resistance to sunitinib [77]. The lncRNA SNHG12 has been described as a critical molecule mediating tumor development in various tumors, including RCC [78], [79], [80], [81]. Liu et al. ...
Sunitinib Renal cell carcinoma Drug resistance Treatment strategies Predictive biomarker 1. Introduction Renal cell carcinoma (RCC) originates from the renal parenchyma (i.e., renal epithelium). (Hsieh et al., 2017b) It is one of the ten most common cancers in the world and the most common ...
Background. Sunitinib is a tyrosine kinase inhibitor used in the treatment of metastatic renal cell carcinoma. The main difficulty related to the treatment is the development of drug resistance follo...
Over the past 5 years, several new immunotherapy treatments have been tested for metastatic renal cell carcinoma (mRCC). Clinical trials assessing combinations of different immunotherapies, or of an immunotherapy with a tyrosine kinase inhibitor (TKI), h
J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007). Article CAS PubMed Google Scholar Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007). Article ...
Sunitinib versus everolimus for non-clear-cell renal cell carcinomadoi:10.1038/nrurol.2016.25Rebecca KelseyNature Reviews Urology